
FMTX
Healthcare · Biotechnology · $1.01B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2022
EPS trend, 90 days to now · -14.6% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 5, 2022 | Before the open | -0.99 | -1.10 | -11.1% |
| May 6, 2022 | Before the open | -1.05 | -0.93 | +11.4% |
| Mar 1, 2022 | Before the open | -0.96 | -1.06 | -10.4% |
| Nov 12, 2021 | Before the open | -0.96 | -0.91 | +5.2% |
| Aug 13, 2021 | Before the open | -0.79 | -0.92 | -16.5% |
| May 14, 2021 | Before the open | -0.76 | -0.76 | 0.0% |
| Mar 30, 2021 | Before the open | -0.80 | -0.68 | +15.0% |
| Nov 12, 2020 | Before the open | -0.68 | -0.67 | +1.5% |
| Aug 13, 2020 | Before the open | -0.74 | -4.58 | -518.9% |
| Apr 8, 2020 | After the close | 0.00 | 0.42 | — |
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic…